Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Sichuan Kelun-Biotech
6990Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People's Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanlimab), A140, and A400; and non-oncology drug candidates primarily to treat immune-mediated diseases, consisting of rheumatoid arthritis and alopecia areata comprising A223, A277, SKB378, and SKB336. The company has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; and Ellipses Pharma Limited. The company was incorporated in 2016 and is headquartered in Chengdu, the People's Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd. Address: No. 666 Xinhua Avenue, Chengdu, China
Analytics
Precio Objetivo de WallStreet
1 677.46 HKDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave 6990
Análisis de dividendos 6990
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout 6990
Valoración de la acción 6990
Finanzas 6990
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |